Abstract: The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.

Abstract: The present disclosure relates generally to biomarkers and peptide arrays, and, more particularly, to a method of using a peptide array to identify biomarkers for an autoimmune disease such as, e.g., Celiac disease. Furthermore, a set of novel biomarkers for Celiac disease, having high sensitivity and specificity, are disclosed in addition to method of treatment using the novel biomarkers.

Abstract: Disclosed is a method that combines high throughput and flexible nature of a cell-free protein microarray with the quantitative capability of surface plasmon resonance to detect>400 different protein interactions in<1 hour. A method of detecting interactions between a targeting agent and one or more proteins of interest is disclosed. The method includes producing a set of proteins of interest using a cell-free protein expression system; providing the set of proteins of interest on a protein microarray wherein each spot in the array comprises a protein of interest; contacting the protein microarray with a targeting agent that binds to one or more of the set of proteins of interest; and detecting the binding of the targeting agent to the set of proteins of interest using surface plasmon resonance imaging (SPRi), thereby detecting the targeting agent and one or more proteins of interest in the micro array.

Abstract: Featured are biomarkers for progressive multifocal leukoencephalopathy (PML). Also provided are methods for reducing the occurrence or severity of PML during immunomodulator therapy or identification of PML in an immunocompromised subject.

Abstract: The present invention relates to methods of diagnosing or prognosing arthritis, specifically methods of diagnosing or prognosing psoriatic arthritis. Also disclosed are methods of diagnosing or prognosing rheumatoid arthritis, and methods of differentiating psoriatic arthritis from rheumatoid arthritis. Specifically, the methods involve determining the quantitative or qualitative level of one or more biomarkers in a biological sample from a subject.

Abstract: The disclosure relates to a method for eliminating interference of theophylline in immunoassay and an immunodetection kit. The method for eliminating interference of theophylline in immunoassay includes: performing an immunoassay in the presence of a theophylline interference-resistant agent, the theophylline interference-resistant agent having a final concentration of 0.1 mg/mL-100 mg/mL, and being selected as at least one component from a group consisting of free 6-mercaptopurine, 6-thioguanine, 8-azguanine, hypoxanthine, adenine, purine, 2,6,8-trioxypurine, adenine nucleotide, and adenosine. The method and the kit can effectively reduce interference of theophylline on immunoassay results.

Abstract: Described herein are compositions and methods useful for isolating compositions that repel insects, including mosquitoes.

Abstract: This disclosure provides methods and compositions for biomolecule corona analysis of biofluids. A biofluid may be contacted with a nanoparticle to form a biomolecule corona, and the composition of the resulting corona may be analyzed. Also provided are methods of preparing a biofluid for corona analysis by serial interrogation.

Abstract: The present disclosure encompasses embodiments of nucleic acids comprising genetic elements which are useful for the detection of diseased cells.

Abstract: An object of the present invention is to provide a method capable of detecting whether a subject has systemic lupus erythematosus (preferably nephrotic syndrome) with high accuracy without performing a renal biopsy, a biomarker for carrying out such detection, and the like. The concentration of 3?,4?-didehydro-3?-deoxycytidine in urine collected from a test subject is measured, and this concentration is compared with a reference concentration for control, which allows to detect whether the above-mentioned test subject has systemic lupus erythematosus (preferably lupus nephritis) with high accuracy.

Abstract: The present disclosure relates to a method for manufacturing a surface-enhanced Raman scattering (SERS)-based substrate for detecting a target substance, by which the surface of a target substance can be easily coated with metal nanoparticles through centrifugation, a substrate for detecting a target substance manufactured thereby, and a method for detecting a target substance using the same.

Abstract: The present invention relates inter alia to the development of monoclonal antibodies against Ambra-1 and methods for determining whether a subject with melanoma has an increased risk of metastasis using said antibodies.